Last reviewed · How we verify
NCT03917082: LALEAST
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Phase 2 trial testing Tamoxifen Citrate in Breast Cancer Female in 290 participants. Participants enrolled and being followed up; not accepting new ones.
1 May 2026
Quick facts
| Lead sponsor | British Columbia Cancer Agency |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 290 |
| Start date | 23 September 2019 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2029 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Tamoxifen Citrate — full drug profile →
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Hormone Receptor Positive Tumor — all drugs for Hormone Receptor Positive Tumor →
Sponsor
British Columbia Cancer Agency
Who can join
51 and older, female only, with Breast Cancer Female or Hormone Receptor Positive Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk of breast cancer; as determined by histopathologic criteria and confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this population, and will not compromise the expected excellent breast cancer specific outcomes for this population.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).
Ohnstad HO, Blix ES, Akslen LA, Gilje B, et al · · 2024 · cited 10× · PMID 38838499 · DOI 10.1016/j.esmoop.2024.103475 -
Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.
Bottosso M, Miglietta F, Vernaci GM, Giarratano T, et al · · 2024 · cited 8× · PMID 38656833 · DOI 10.1158/1078-0432.ccr-23-4020 -
Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey.
Alzahrani M, Clemons M, Chang L, Vendermeer L, et al · · 2021 · cited 4× · PMID 35049675 · DOI 10.3390/curroncol29010001
Verify or expand the search:
- PubMed search for NCT03917082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tamoxifen Citrate
Trials testing the same drug.
- NCT04129216 — The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer · Phase 2 · completed
- NCT03238703 — Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer · Phase 4 · withdrawn
- NCT02993159 — Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Si · Phase 2 · completed
- NCT02311933 — Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Recept · Phase 2 · active not recruiting
- NCT02197897 — Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors · Phase 2 · completed
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other British Columbia Cancer Agency trials
Trials by the same sponsor.
- NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
- NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
- NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
- NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03917082 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing